Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2011

Open Access 01-12-2011 | Research

Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma

Authors: Zhouxun Chen, Suchen Gu, Bogusz Trojanowicz, Naxin Liu, Guanbao Zhu, Henning Dralle, Cuong Hoang-Vu

Published in: World Journal of Surgical Oncology | Issue 1/2011

Login to get access

Abstract

Background

The aim of this study was to clarify the clinical significance of TM4SF members CD9, CD63 and CD82 in human gastric carcinoma.

Methods

By employing RT-PCR and immunohistochemistry, we studied the expression of CD9, CD63 and CD82 in 49 paired tissue specimens of normal gastric mucosa and carcinoma. All tissues were obtained from patients who underwent curative surgery.

Results

All normal gastric epithelium and gastric ulcer tissues strongly expressed transcripts and proteins of CD9, CD63 and CD82 as compared with corresponding controls. We found a significant correlation between CD63 mRNA level and different pM statuses (P = 0.036). Carcinomas in M0 stage revealed a stronger expression of CD63 than carcinomas in M1 stage. Expression of CD9 protein was found significantly stronger in pN0, pM0 than in advanced pN stages (P = 0.03), pM1 (P = 0.013), respectively. We found the relationship between CD63 expression, gender (p = 0.09) and nodal status (p = 0.028), respectively. Additionally, advanced and metastasized tumor tissues revealed significantly down-regulated CD82 protein expression (p = 0.033 and p = 0, respectively), which correlated with the tumor pTNM stage (p = 0.001).

Conclusion

The reduction of CD9, CD63 and CD82 expression are indicators for the metastatic potential of gastric carcinoma cells. Unlike their expression in other tumor types, the constitutive expression of CD63 may indicate that this factor does play a direct role in human gastric carcinogenesis.
Appendix
Available only for authorised users
Literature
1.
Wright MD, Tomlinson MG: The ins and outs of the transmembrane 4 superfamily. Immunol Today. 1994, 15: 588-594. 10.1016/0167-5699(94)90222-4.CrossRefPubMed
2.
Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med. 1993, 177: 1231-1237. 10.1084/jem.177.5.1231.CrossRefPubMed
3.
Dong JT, Suzuki H, Pin SS: Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996, 56: 4387-4390.PubMed
4.
Radford KJ, Thorne RF, Hersey P: CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta1 integrins in human melanoma. Biochem Biophys Res Commun. 1996, 222: 13-18. 10.1006/bbrc.1996.0690.CrossRefPubMed
5.
Maecker HT, Todd SC, Levy S: The tetraspanin superfamily: molecular facilitators. FASEB J. 1997, 11 (6): 428-442.PubMed
6.
Boucheix C, Rubinstein E: Tetraspanins. Cell Mol Life Sci. 2001, 58 (9): 1189-1205. 10.1007/PL00000933.CrossRefPubMed
7.
Miller WJ, Gonzalez-Sarmiento R, Kersey JH: Immunoglobulin and T-cell receptor gene rearrangement in blast crisis of chronic myelocytic leukemia. Exp Hematol. 1988, 16 (10): 884-888.PubMed
8.
Berditchevski F: Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci. 2001, 114: 4143-4151.PubMed
9.
Berditchevski F, Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol. 1999, 146: 477-492. 10.1083/jcb.146.2.477.PubMedCentralCrossRefPubMed
10.
Gutierrez-Lopez MD, Ovalle S, Yanez-Mo M: A functionally relevant conformational epitope on the CD9 tetraspanin depends on the association with activated h1 integrin. J Biol Chem. 2003, 278: 208-218.CrossRefPubMed
11.
Longo N, Yáñez-Mó M, Mittelbrunn M, de la Rosa G, Muñoz ML, Sánchez-Madrid F, Sánchez-Mateos P: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood. 2001, 98: 3717-3726. 10.1182/blood.V98.13.3717.CrossRefPubMed
12.
Peñas PF, García-Díez A, Sánchez-Madrid F, Yáñez-Mó M: Tetraspanins are localized at motility-related structures and involved in normal human keratinocyte wound healing migration. J Invest Dermatol. 2000, 114: 1126-1135. 10.1046/j.1523-1747.2000.00998.x.CrossRefPubMed
13.
Higashiyama M, Taki T, Ieki Y: Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res. 1995, 55: 6040-6044.PubMed
14.
Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M: Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol. 1998, 153: 973-983. 10.1016/S0002-9440(10)65639-8.PubMedCentralCrossRefPubMed
15.
Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res. 1998, 4: 1507-1510.PubMed
16.
Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995, 268: 884-886. 10.1126/science.7754374.CrossRefPubMed
17.
Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M, Büchler MW: KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastasis. Cancer Res. 1996, 56: 4876-4880.PubMed
18.
Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J, Russell PJ: Loss of KAI1 messenger RNA in both high grade and invasive human bladder cancers. Clin Cancer Res. 1997, 3: 1045-1049.PubMed
19.
Ow K, Delprado W, Fisher R, Barrett J, Yu Y, Jackson P, Russell PJ: Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. J Pathol. 2000, 191: 39-47. 10.1002/(SICI)1096-9896(200005)191:1<39::AID-PATH580>3.0.CO;2-K.CrossRefPubMed
20.
Yang X, Wei L, Tang C, Slack R, Montgomery E, Lippman M: KAI1 Protein Is Down-Regulated during the Progression of Human Breast Cancer. Clin Cancer Res. 2000, 6: 3424-3429.PubMed
21.
Hashida H, Takabayashi A, Tokuhara T: Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer. 2002, 97 (4): 518-525. 10.1002/ijc.1625.CrossRefPubMed
22.
Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC: Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res. 1999, 59 (22): 5724-5731.PubMed
23.
Uzawa K, Ono K, Suzuki H: High Prevalence of Decreased Expression of KAI1 Metastasis Suppressor in Human Oral Carcinogenesis. Clin Cancer Res. 2002, 828-835.
24.
Radford KJ, Thorne RF, Hersey P: Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol. 1997, 158 (7): 3353-3358.PubMed
25.
Radford KJ, Mallesch J, Hersey P: Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer. 1995, 62 (5): 631-635. 10.1002/ijc.2910620523.CrossRefPubMed
26.
Chen Z, Mustafa T, Trojanowicz B: CD82 and CD63 in thyroid cancer. Int J Mol Med. 2004, 14 (4): 517-27.PubMed
27.
Miyake M, Nakano K, Itoi SI, Koh T, Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res. 1996, 56: 1244-1249.PubMed
28.
Hotta H, Ross AH, Huebner K: Molecular cloning and characterization of an antigen associated with early stage of melanoma tumor progression. Cancer Res. 1988, 48: 2955-2962.PubMed
29.
Liu WM, Zhang XA: KAI1/CD82, a tumor metastasis suppressor. Cancer lett. 2006, 240: 183-194. 10.1016/j.canlet.2005.08.018.CrossRefPubMed
30.
Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, Büchler MW: Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer. 1998, 79: 349-355. 10.1002/(SICI)1097-0215(19980821)79:4<349::AID-IJC7>3.0.CO;2-V.CrossRefPubMed
31.
Su JS, Arima K, Hasegawa M: Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Int J Urol. 2004, 11: 74-82. 10.1111/j.1442-2042.2004.00752.x.CrossRefPubMed
32.
Bouras T, Rauman AG: Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol. 1999, 188: 382-388. 10.1002/(SICI)1096-9896(199908)188:4<382::AID-PATH365>3.0.CO;2-O.CrossRefPubMed
33.
Maurer CA, Graber HU, Friess H: Reduced expression of the metastasis suppressor gene KAI1 in advanced colon cancer and its metastases. Surgery. 1999, 126: 869-880. 10.1016/S0039-6060(99)70028-0.CrossRefPubMed
34.
Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M: Correlation of CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Re. 1996, 56: 1751-1755.
35.
Berditchevski F, Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol. 1999, 146: 477-492. 10.1083/jcb.146.2.477.PubMedCentralCrossRefPubMed
36.
Hemler ME: Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005, 6 (10): 801-11. 10.1038/nrm1736.CrossRefPubMed
37.
Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, Yamada KM: Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Bio. 1999, 146: 386-403.CrossRef
38.
Kolesnikova TV, Stipp CS, Rao RM, Lane WS, Luscinskas FW, Hemler ME: EWI-2 modulates lymphocyte integrin a4β1fuctions. Blood. 2004, 103: 3013-3019. 10.1182/blood-2003-07-2201.CrossRefPubMed
39.
Odintsova E, Sugiura T, Beditchevski F: Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol. 2000, 10: 1009-1012. 10.1016/S0960-9822(00)00652-7.CrossRefPubMed
Metadata
Title
Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma
Authors
Zhouxun Chen
Suchen Gu
Bogusz Trojanowicz
Naxin Liu
Guanbao Zhu
Henning Dralle
Cuong Hoang-Vu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2011
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-9-43

Other articles of this Issue 1/2011

World Journal of Surgical Oncology 1/2011 Go to the issue

Case report

Extracranial propagation of glioblastoma with extension to pterygomaxillar fossa

Research

The versatile application of cervicofacial and cervicothoracic rotation flaps in head and neck surgery

Case report

Successful one stage operation for a synchronous, duodenal carcinoma, colonic carcinoma and renal oncocytoma in an adult patient

Case report

Bilateral adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1 (MEN1) and a novel mutation in the MEN1 gene

Case report

Popliteal lymph node dissection for metastatic squamous cell carcinoma: a case report of an uncommon procedure for an uncommon presentation

Technical innovations

Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor